Bruker (NASDAQ:BRKR) Shares Gap Down – Here’s What Happened

Shares of Bruker Corporation (NASDAQ:BRKR) gapped down before the market opened on Tuesday . The stock had previously closed at $64.31, but opened at $54.07. Bruker shares last traded at $52.87, with a volume of 1,433,303 shares.

Analysts Set New Price Targets

A number of research analysts have issued reports on BRKR shares. Wolfe Research assumed coverage on shares of Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. Barclays upped their price target on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Citigroup lifted their price objective on Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their target price on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $56.79.

Bruker Trading Down 18.0%

The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The business has a fifty day simple moving average of $58.52 and a 200 day simple moving average of $46.70. The stock has a market cap of $8.03 billion, a price-to-earnings ratio of -218.50, a PEG ratio of 2.01 and a beta of 1.28.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s payout ratio is currently -83.33%.

Institutional Trading of Bruker

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new position in shares of Bruker during the 4th quarter worth $26,000. Allworth Financial LP increased its stake in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the last quarter. Essential Partners LLC acquired a new position in shares of Bruker during the 1st quarter valued at about $36,000. Parallel Advisors LLC boosted its position in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new stake in Bruker in the fourth quarter valued at approximately $50,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.